Target 2035 - an update on private sector contributions

Abstract

Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging 'open' principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.

Fig. 1. Current analysis of the global scope of chemical probes. The percentage of the proteome that is predicted to be ligandable has been derived from canSAR; it calculates the ligandability of all proteins using 3D structures from either the PDB and/or AlphaFold Protein Structure Database. The liganded proteome has been calculated assuming that a protein is liganded if it has a small molecule in public chemical databases with a binding or inhibition activity more potent than 10 micromolar. The human targets that can be currently studied with a chemogenomics library or a chemical probe have been calculated from public databases using the potency, selectivity and cell activity thresholds displayed. This analysis does not include data from patents unless they have been curated in ChEMBL or BindingDB.

Fig. 2. Private sector contributions to Open Science. The resources described by industry are summarized. Industry hosts a diverse set of open innovation programs, co-develop and donate pharmacogenomic tools, and often conduct off-target profiling. All chemical probes related to the SGC are listed here https://www.thesgc.org/chemical-probes, while the donated probes are listed here https://www.sgc-ffm.uni-frankfurt.de/. Between 1st May 2020 and 30th April 2025, the co-developed and donated probes and ligands will also be hosted on dedicated EUbOPEN web-pages^g,h. Where relevant the links to commercial suppliers are listed. ^ahttps://www.bayer.com/en/pharma/chemical-probes-open-access; ^bhttps://opnme.com/; ^chttps://www.wipo.int/edocs/pubdocs/en/wipo_pub_research_storybook_2019.pdf; ^dhttps://www.emdgroup.com/en/research/open-innovation.html; ^ehttps://ximbio.com/reagent/157681/the-kinase-chemogenomic-set-kcgs; ^fhttps://www.novonordisk.com/partnering-and-open-innovation/open-innovation/innovation-challenges.html; ^ghttps://www.eubopen.org/chemical-probes, ^hhttps://www.eubopen.org/chemical-handles.